Cargando…

Anticancer and antiproliferative efficacy of a standardized extract of Vaccinium macrocarpon on the highly differentiating oral cancer KB cell line athwart the cytotoxicity evaluation of the same on the normal fibroblast L929 cell line

BACKGROUND AND OBJECTIVES: The perpetual search is on to find botanical complementary adjuncts to the conventional therapies used that is not only cost-effective but also reduces side effects associated with conventional synthetic drugs that are available in the market. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankola, Anil V., Kumar, Vaibhav, Thakur, Simran, Singhal, Richa, Smitha, T, Sankeshwari, Roopali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802834/
https://www.ncbi.nlm.nih.gov/pubmed/33456234
http://dx.doi.org/10.4103/jomfp.JOMFP_129_20
Descripción
Sumario:BACKGROUND AND OBJECTIVES: The perpetual search is on to find botanical complementary adjuncts to the conventional therapies used that is not only cost-effective but also reduces side effects associated with conventional synthetic drugs that are available in the market. The aim of this study was to assess the in vitro anticancer efficacy of hydroalcoholic fruit extract of cranberry against oral cancer KB cell line by Di-Methyl Thiazoldiphenyl Tetrazolium bromide assay (MTT) assay and its cytotoxicity on normal fibroblast cells. MATERIALS AND METHODS: Vaccinium macrocarpon extract was prepared using a hydroethanolic solvent (water – 30%:ethanol – 70%) using the standardized maceration protocol. Standard KB and normal fibroblast (L929) cell lines were used. The minimum lethal effect of the extract was calculated using the MTT cytotoxicity assay. RESULTS: The extract shows a satisfactory antiproliferative effect on the KB cell line and a higher cell viability percentage of the normal fibroblast cell line. CONCLUSION: V. macrocarpon can prove to be an adjunct to the existing anticancer drug therapy against oral cancer KB cell line.